Todd Friedman | executive |
Christian Henry | executive |
Susan Kim | executive |
Daniel Brennan | analyst |
Kyle Mikson | analyst |
John Sourbeer | analyst |
Jack Meehan | analyst |
Douglas Schenkel | analyst |
Sung Ji Nam | analyst |
Eve Burstein | analyst |
Ross Osborn | analyst |
Tejas Savant | analyst |
Subhalaxmi Nambi | analyst |
Rachel Vatnsdal Olson | analyst |
Mason Carrico | analyst |
Hello, and welcome to the PacBio Fourth Quarter 2023 Earnings Conference Call. [Operator Instructions] I would now like to hand the call to Todd Friedman, Senior Director, Investor Relations. Please go ahead.
Good afternoon, and welcome to PacBio's fourth quarter 2023 earnings conference call. Earlier today, we issued a press release outlining the financial results we will be discussing on today's call, a copy of which is available on the Investor section of our website at www.pacb.com or is furnished on form 8-K available on the Securities and Exchange Commission website at www.scc.gov. With me today are Christian Henry, President and Chief Executive Officer; and Susan Kim, Chief Financial Officer. On today's call, we will make forward-looking statements, including statements regarding predictions, progress, estimates, plans, intentions, guidance, and others, including expectations with respect to our growth potential, instrument and consumable sales, and GAAP and non-GAAP guidance.